“Highly precise”: Telix’s Phase III ZIRCON study on kidney cancer imaging published in The Lancet Oncology Page 1

MELBOURNE, Australia, September 11, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON¹
Study was published in The Lancet Oncology, reports that Telix's first-in-class PET test system² Active ingredient, TLX250-CDx (Zircaix³,
⁸⁹Zr-girentuximab) is highly reliable in the detection and characterization of clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal tumors (IRM).

In this peer-reviewed manuscript, Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues report the results of this prospective, open-label, multicenter Phase III study in which 300 patients with IRM ≤7 cm (cT1) received TLX250-CDx. The authors conclude that TLX250-CDx “has a favorable safety profile and is a highly accurate, noninvasive imaging modality for the detection and characterization of ccRCC that has the potential to be practice-changing.”